NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9

India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. This cap, effective from November 9, applies to all listed drugs, including Atezolizumab and Bevacizumab. Manufacturers must adjust prices if they exceed the newly calculated maximum retail price. Compliance will be monitored by state drug controllers and hospitals, which play a significant role in drug supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ABuEGc
via IFTTT